$2950 | Single User
$5900 | Site License
$8850 | Enterprise License

PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 [Report Updated: 10-07-2017]

Published by Delve Insight: 10 Jul 2017 | 105553 | In Stock

Introduction

DelveInsight’s, “PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017”, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors.

This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with around 47+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also assesses the PD-1 and PD-L1 Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 36+ active companies involved in the therapeutic development of the products.

Scope

• The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors

• The report provides the marketed drugs information including its sales, development activities and details of patent expiry

• The report provides the insight of current and future market for PD and PD-L1 inhibitors

• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

• Coverage of the PD-1 and PD-L1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

• The report reviews key players involved in the therapeutics development for PD-1 and PD-L1 Inhibitors and also provide company profiling

• The report also gives the information of dormant pipeline projects

• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages

• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy

• Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

• Complete MOA intelligence and complete understanding over therapeutics development for PD-1 and PD-L1 Inhibitors

• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.

• Devise corrective measures for pipeline projects by understanding PD-1 and PD-L1 Inhibitors pipeline depth and focus of Indication therapeutics

• Developing strategic initiatives to support your drug development activities.

• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.

• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

PD-1 and PD-L1 Inhibitors Therapy Pipeline scenario

Current Prominent Research Areas and Key Players

Collaborations details and Deal values

Technologies and Targeted antigens

Pipeline product profiles CAR-T Technologies and Targeted Antigens

Licensing opportunities

Market Drivers and Barriers

SWOT Analysis

Table of Contents
for PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 [Report Updated: 10-07-2017]

  • Introduction

    Executive Summary

    Programmed Death 1 (PD-1)

    Programmed Death Ligand 1 (PD-L1)

    Role of PD-1 and PD-L1 pathways

    MOA of PD-1 and PD-L1 inhibitors

    Significance of PD-1 and PD-L1 inhibitors

    PD-1 and PD-L1 Active Therapy Areas & Epidemiology

    Metastatic Renal Cell Carcinoma

    Squamous Cell Carcinomas of the Head and Neck

    Metastatic Colorectal Cancer

    Non-Small Cell lung cancer

    Biomarkers - PD-1 and PD-L1 inhibitors

    Market Overview

    Comparative Analysis of Pipeline &Marketed Drugs

    Marketed Product of PD-1 and PD-L1 drugs –Overview

    Marketed Drug Candidate Profiles

    Pembrolizumab

    Nivolumab

    Atezolizumab

    Marketed Drugs Sales

    Details of Patent Expiry of Marketed Drugs

    Current and Future Market for PD and PD-L1 inhibitors

    Challenges and Barriers associated with use of PD and PD-L1 inhibitors

    PD-1/PD-L1Combinations Creating Boom

    Pipeline Therapeutics

    An overview of pipeline products

    Pipeline Therapeutics Overview

    Therapeutics under Development by MOA

    Therapeutics under Development by Companies

    Last Stage Products (Phase III and Filed)

    Comparative Analysis

    Mid Stage Products (Phase II)

    Comparative Analysis

    Early Stage Products (Phase I and IND)

    Comparative Analysis

    Pre-Clinical and Discovery Products

    Comparative Analysis

    Unknown Stages Molecules

    Therapeutic Assessment of pipeline

    Therapeutics under Development by Product Type

    Therapeutics under Development by Phase for Monotherapy

    Therapeutics under Development by Phase for Combination therapy

    Therapeutics under Development by Molecule Type

    Assessment by Stage and Molecule Type

    Therapeutics under Development by Route of Administration

    Assessment by Stage and Route of Administration

    Dormant Products

    Comparative Analysis

    SWOT Analysis

    Appendix

    Methodology

    Consulting Services

    About DelveInsight

    Contact Us

    Disclaimer

List Of Tables
in PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 [Report Updated: 10-07-2017]

Table 1: Marketed and Pipeline drugs forPD-1 and PD-L1 Drugs, 2017

Table 2: PD-1 Marketed Drugs, 2017

Table 3: Sales of Marketed drugs, 2017

Table 4: Details of patent expiry of marketed molecules, 2017

Table 5: Merck’s drug- Keytruda (Pembrolizumab) Partners for Combination Therapies

Table 6:Bristol Myers Squibb’s drug-Opdivo (nivolumab) Partners for Combination Therapies

Table 7: Roche’s drug-Atezolizumab (MPDL-3280A) Partners for Combination Therapies

Table 8: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2017

Table 9: ComparativeTable forPD-1 and PD-L1 inhibitors Drugs, 2017

Table 10: Number of Products under Development by Companies, 2017

Table 11: Last Stage Products (Phase III and Filed),2017

Table 12: Mid Stage Products (Phase II), 2017

Table 13: Early Stage Products (Phase I and IND), 2017

Table 14: Pre-Clinical and Discovery Products, 2017

Table 15: Number of Products by Product Type for PD-1 and PD-L1 Inhibitors, 2017

Table 16: Number of Monotherapy Products for PD-1 and PD-L1 inhibitors, 2017

Table 17:Number of Combination therapy Products forPD-1 and PD-L1 inhibitors, 2017

Table 18: Number of Products under Development by Molecule Type, 2017

Table 19: Assessment by Stage and Molecule Type, 2017

Table 20:Number of Products under Development by Route of Administration, 2017

Table 21:Assessment by Stage and Route Of Administration, 2017

Table 22: Dormant Products, 2017

List Of Figures, Charts and Diagrams
in PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 [Report Updated: 10-07-2017]

Figure 1:Marketed and Pipeline drugs forPD-1 and PD-L1 Drugs, 2017

Figure 2: Sales of marketed drugs, 2017

Figure 3: Details of patent expiry of marketed molecules, 2017

Figure 4: Number of Products under Development forPD-1 and PD-L1 inhibitors Drugs, 2017

Figure 5: Comparative Graph forPD-1 and PD-L1 inhibitors Drugs, 2017

Figure 6:Last Stage Products (Phase III), 2017

Figure 7: Mid Stage Products (Phase II), 2017

Figure 8: Early Stage Products (Phase I and IND), 2017

Figure 9:Pre-Clinical and Discovery Products, 2017

Figure 10: Number of Products by Product Type forPD-1 and PD-L1 Inhibitors, 2017

Figure 11: Number of Monotherapy Products forPD-1 and PD-L1 inhibitors, 2017

Figure 12: Number of Combination therapy Products forPD-1 and PD-L1 inhibitors, 2017

Figure 13: Percentage of pipeline drugs by Molecule Type (%), 2017

Figure 14: Assessment by Stage and Molecule Type, 2017

Figure 15:Percentage of pipeline drugs by Route of Administration(%), 2017

Figure 16: Assessment by Stage and Route of Administration, 2017

Figure 17: Dormant Products, 2017

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

105553 | DISR0001

Number of Pages

311

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Is Esperion's ETC-1002 a viable threat to the PCSK9 inhibitors if mid-stage data are replicated in Phase III studies?
Scope Last week saw Esperion Therapeutics release promising Phase IIb data for its oral hypercholest...
25 Mar 2015 by FirstWord Pharma USD $695 More Info
Physician Views: Do cardiologists agree with payer rhetoric on PCSK9 inhibitors?
Scope Last week, CVS Health became the second pharmacy benefit manager (PBM) to publicly highlight t...
25 Feb 2015 by FirstWord Pharma USD $695 More Info
Physician Views: What impact will the IMPROVE-IT study have on the treatment landscape?
Scope As many have speculated, final data from Merck & Co.'s long-awaited IMPROVE-IT study has impli...
20 Nov 2014 by FirstWord Pharma USD $695 More Info
Physician Views: When and where do oncologists see palbociclib fitting into the ER+, HER2- breast cancer landscape?
Scope Analysts believe palbociclib is likely headed for an accelerated approval to treat a subset of...
28 Aug 2014 by FirstWord Pharma USD $695 More Info
Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?
Scope The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in par...
05 May 2014 by FirstWord Pharma USD $695 More Info
Biosimilar Index: Tracking the Biosimilar Development Landscape
IntroductionFirstWord’s Biosimilar Index is a comprehensive drug intelligence service that provides ...
01 Apr 2014 by FirstWord Pharma USD $5,295 More Info
Market Access for Orphan Drugs: assessing the global landscape
IntroductionTheir development costs can be high and the market is relative small, yet orphan drugs r...
01 Dec 2013 by FirstWord Pharma USD $695 More Info
Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook
IntroductionThe worldwide hepatitis C (HCV) market is forecast to grow from .7 billion in 2012 to ...
01 Dec 2013 by FirstWord Pharma USD $4,995 More Info
Physician Views: Life beyond statins – what opportunity for PCSK9 inhibitors?
ScopeWith Sanofi and Regeneron Pharmaceuticals set to unveil the first Phase III data for their expe...
01 Oct 2013 by FirstWord Pharma USD $695 More Info
Social and Mobile Pharma - the State of the Digital Landscape
IntroductionTightly-regulated and conservative in outlook, the pharmaceutical industry has largely b...
01 Nov 2012 by FirstWord Pharma USD $695 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 [Report Updated: 10-07-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data